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Structural misassignments are often seen for complex natural products, but this can also be an issue with
seemingly simpler structures. In this paper, we describe how, using a 15N-labelled analogue, we estab-
lished that the Dimroth rearrangement can occur in imidazo[1,2-a]pyrimidines and result in an incorrect
regiochemical assignment of such compounds. These studies supported a rearrangement mechanism
involving addition of hydroxide ion followed by ring opening. It was also observed that C(2) and C(3)
substituted regioisomers could be readily distinguished using 1H NMR spectroscopy.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The imidazo[1,2-a]pyrimidine scaffold is an emerging hetero-
bicyclic scaffold of signiﬁcant interest in the contemporary me-
dicinal chemistry literature. In recent years there have been an
increasing number of reports of activity of this class of compound
against various different targets (mGlu2, mGlu5, D1, Lp-PLA2, TNF,
PI3K, SUV39H2, IAP-BIR and DPP-4) [1e9] and in multiple thera-
peutic areas (AIDS, antiparasitic, antiproliferative, autotaxine
associated disease, Peyronie's disease, spinal muscular atrophy)
[10e15], as well as their use as blue ﬂuorescent light emitters [16].
A more comprehensive list on the potential therapeutic areas can
be found in a recent review on synthetic approaches for this scaf-
fold [17]. Furthermore, imidazo[1,2-a]pyrimidines are found in a
number of commercially available compound libraries, probably
due to their privileged physicochemical properties and their
resemblance to natural substrates such as purines.University of Oxford, Chem-
1 3TA, UK.
Russell).
r Ltd. This is an open access articlA feature of aza heterocycles such as imidazo[1,2-a]pyrimidines
is that they can undergo the Dimroth rearrangement when sub-
jected to appropriate reaction conditions. This transformation is
described as a translocation of two heteroatoms in a heterocyclic
system with or without changes in the ring structure, and it is an
often undesired side reaction that occurs, usually in basic media,
and as a result can lead to structure misassignments for the prod-
ucts. Even though the ﬁrst mention of a Dimroth-type ring opening
in the literature dates back to 1888 [18], it is not uncommon for
incomplete data to be provided for new analogues and regio-
chemical assignments made by comparison (often erroneously)
with existing literature data, as the use of more complicated and
time-consuming X-ray studies to unequivocally assign the regio-
chemistry is frequently not carried out.
Many factors inﬂuence the propensity of aza-heterocycles to
undergo the Dimroth rearrangement. In general, decreasing the p
electron density of the fused 6-ring increases the rate of rear-
rangement. Thus, aza-substitution in the imidazo[1,2-a]pyridine
system to give the corresponding imidazo[1,2-a]pyrimidine leads
tomore facile nucleophilic attack at position 5 (Fig.1), and the same
is observed with electron withdrawing groups. As a result 2-e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Postulated mechanism of the Dimroth rearrangement under basic conditions in
the imidazo[1,2-a]pyrimidine ring.
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under alkaline conditions, however, the same ring system will
undergo a rearrangement in the presence of electron withdrawing
substituents such as a nitro group at C6 or C8 [19]. The rate of
rearrangement is dependent on pH, with the product distribution
usually dependent on the substituents [20,21]. Of the rearrange-
ments that have been described for the imidazo[1,2-a]pyrimidine
core [20,22e25], the most common occurrence was with the use of
hydrolytic [23,25] or haloformic conditions [22,24], as outlined
above. The Dimroth rearrangement can also take place in acidic
conditions or with photo-activation in other aza-heterocycles and
especially triazolo species, although such transformations have not
been observed with the imidazo[1,2-a]pyrimidine system.
Mechanistic aspects of the rearrangement have been described,
including some important kinetic and computational calculations,
which have been provided by Guerret et al. [20] identifying the
minimal characteristics of aza-heterocycles to undergo the Dimroth
rearrangement. In this study the authors recognise the possibilities
of water addition by other mechanisms such as 1,4-addition or
tautomerism, but conclude their data best supports a mechanism
involving nucleophilic attack at C5/ring opening (as depicted in
Fig. 1).
Interestingly, in surveying the literature data on this class of
heterocycle, we noted that there was surprisingly little supporting
evidence for the assigned structures, particularly in the patent
literature where often more limited data are provided. In most
cases the authors assigned either of the two regioisomers based on
previous observations. Moreover, there were frequently discrep-
ancies in the spectroscopic data even where the same regioisomer
was claimed. Given the emergence of the scaffold in multiple
commercially available compound libraries, and the increasing
frequency with which these compounds are mentioned in the
literature, it is crucial to be able to distinguish between the two
possible regioisomeric products, as well as to characterize the
conditions that induce the rearrangement.
2. Results and discussion
We became interested in these ring systemswhilst investigating
access to a range of imidazo[1,2-a]pyrimidine analogues
substituted at C2 and C6. We initially followed a route wherein the
bicyclic core was formed by reaction of 2-amino-5-iodopyrimidine
with ethyl bromopyruvate. A Suzuki reaction was then followed by
a direct conversion of esters 2 to the corresponding amides 3
(Scheme 1, Route A). A small series of amide analogues was pre-
pared using this method (compounds 3a, 3d, 3e Table 1). However,
when an alternative route was employed involving initial hydro-
lysis of esters 2 followed by amide coupling of the resultant car-
boxylic acids 4 (Scheme 1, Route B, compounds 5a-e, Table 1) we
noted that there was a discrepancy in the analytical data of the
products formed. For example, the products 3a and 5a were of the
same mass, but their NMR spectra and TLC retention factors
differed signiﬁcantly. We suspected this may have been caused by aDimroth rearrangement of ester intermediate 2a. However, we
needed to unambiguously determine the regiochemistry within
products 3a and 5a.
The reaction of 2-aminopyrimidines with a-halocarbonyl spe-
cies to afford the C2 regioisomer as the kinetic product is very well
precedented, and mixtures of isomers can usually be obtained in
different ratios by subsequent rearrangement under aqueous basic
conditions [20,25,26]. Given that intermediates 1 and 2 and prod-
ucts 3 were all obtained as a single regioisomer, and that each
transformation in Route A was conducted under anhydrous con-
ditions, we initially tentatively assigned the structures as the C2-
substituted regioisomers. Regioisomer 3 could also be accessed
via a different route avoiding a basic saponiﬁcation step wherein
the imidazo[1,2-a]pyrimidine-2-carboxylic acids 7a-c were syn-
thesized directly from reaction of 2-aminopyrimidines 6a-c with
bromopyruvic acid. Amide coupling of carboxylic acids 7a-c gave
products 3a-e each as a single regioisomer (Scheme 1, Route C,
Table 1).
In Route B we reasoned that the isomerization must have
occurred either at the hydrolysis or the amide formation steps,
most plausibly at the ester hydrolysis step as this proceeded under
aqueous basic conditions. We therefore tentatively assigned 4a and
5a as the C3 substituted regioisomers. However, on comparing the
1H NMR data for 3a, 4a and 5awith very similar compounds in the
literature assigned as C2 regioisomers we noticed a discrepancy
(Supplementary Information, Table 2, Entries 1 and 3) [27]. These
compounds had been prepared using basic hydrolysis conditions
from the corresponding ethyl ester, but no supporting evidence for
the regiochemical assignment was provided. However, their data
was not in agreement with several other literature sources
reporting spectroscopic data for the C2 regioisomer where a sig-
niﬁcant deshielding effect in the shift of H-5 is observed with
electron withdrawing substituents at C3 [22e24]. As these data
were contradictory and there are no unambiguous assignments for
both regioisomers made possible through correlation with tech-
niques such as X-ray crystallography, we decided to prepare a small
array of unlabelled and 15N-labelled analogues both to use as
mechanistic probes and to attempt to assign unambiguously the
regiochemistry of each C2 and C3 isomer (Scheme 2).
Thus, samples of 14N-C2-substituted ethyl ester and the corre-
sponding carboxylic acid were prepared following a two-step
protocol from 2-amino-5-iodopyrimidine. A Suzuki cross-
coupling with phenylboronic acid afforded 2-aminopyrimidine in-
termediate 6 and subsequent cyclisation with either ethyl bromo-
pyruvate or bromopyruvic acid gave the desired 2-substituted
imidazo[1,2-a]pyrimidines 8a and 8b respectively. The 15N-labelled
counterparts 8c and 8d were accessed via a three-step procedure
from 5-bromo-2-chloropyrimidine involving Suzuki cross-
coupling, substitution at C2 using 15NH4Cl under mildly basic
conditions and cyclisation with either ethyl bromopyruvate or
bromopyruvic acid. To ensure that no rearrangement had occurred
under these latter reaction conditions, samples of 6, 8a and 8bwere
also prepared by this route: analytical data were shown to be
identical (Scheme 2). Formation of 3-carboxylic acid 11a as a single
regioisomer was achieved by subjecting ethyl ester 8a to the basic
saponiﬁcation conditions described above (Scheme 3).
The regiochemistry within 11a was conﬁrmed by full assign-
ment and NOESY correlations (Supporting Information). As ex-
pected, there are NOE correlations between the two protons of the
pyrimidine ring and the phenyl ortho protons (11a), while in the
case of 8b there is a further correlation between H-5 and H-3
(Fig. 2). This was further corroborated by 15N NMR, as described
below. It is also apparent that there is deshielding of H-5 in 3-
regioisomers and this was observed in all the analogues synthe-
sized (Supplementary Table 1). Interestingly this effect was more
Scheme 1. Synthetic routes towards carboxylic acid derivatives of imidazo[1,2-a]pyrimidines. a. 1) ethyl bromopyruvate, THF, rt, 2 h, 2) EtOH, 95 C, 1 h b. ethyl bromopyruvate,
EtOH, 95 C, 6 h, 52% over two steps c. arylboronic acid, Pd(OAc)2, P(o-Tol)3, CsF, DME, 90 C, 20 h, 22e75% d. CaCl2, amine, MeOH, 70 C, 1 h, 10e34% e. NaOH, EtOH, THF, H2O, 60 C,
3 h, f. amine, HBTU, TEA, MeCN, rt, 2 h, 17e64% for 3a-e, 37e45% over two steps for 5a-e, g. arylboronic acid, Pd(dppf)Cl2, K2CO3, dioxane/H2O, rt, 15min, 73e93% h. bromopyruvic
acid, DMF, rt, 4d, 67e74%.
Table 1
Amides 3a-e and 5a-e produced via Routes A and B in Scheme 1.
Cpd R1 R2 R3 Route Yield
3a 3-OMe N-morpholino A 33%
C 64%
3b 3-Cl,4-Cl Me Et C 40%
3c 3-CF3 Me Et C 17%
3d 3-OMe Me Et A 10%
C 49%
3e 3-OMe N-pyrrolydinyl A 63%
5a 3-OMe N-morpholino B 37% (from 2a)
5b 3-Cl,4-Cl Me Et B 39% (from 2a)
5c 3-CF3 Me Et B 39% (from 2a)
5d 3-OMe Me Et B 41% (from 2a)
5e 3-OMe N-pyrrolydinyl B 45% (from 2a)
Scheme 2. Synthetic routes for both the 15N-labelled and 14N-imidazo[1,2-a]pyrimi-
dines. a. PhB(OH)2, Pd(OAc)2, K3PO4, EG, 80 C, 2 h, 90% b. ethyl bromopyruvate or
bromopyruvic acid, DMF, rt, 4d, 18e41% c. NH4Cl, 1M NaOH,150 C, MW, 30min, 61% d.
PhB(OH)2, Pd(OAc)2, Na2CO3, H2O/EtOH, 45 C, 0.5 h, 80% e. 15NH4Cl, 1M NaOH, 150 C,
MW, 30min, 81%.
Scheme 3. Products obtained from the ester derivatives 8a or 8c under different
conditions. a. 5% NaOH, MeOH, H2O, 70 C, 18 h, 0% b. NaOH, EtOH, THF, H2O, 60 C, 6 h,
51e55% c. EtONa, EtOH, 95 C, 20 h, 26e29%.
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d4, MeCN-d3 or DMSO‑d6) where the corresponding increase in
chemical shift was greater than 1 ppm, possibly due to the presence
of acid in CDCl3. Nomajor differences were observed in the shifts of
the other two protons of interest, H-7 and H-2 or H-3. Assignment
of the pyrimidine protons could be readily achieved from their
coupling constant (2e3Hz) and it was also observed that the 13C
chemical shifts were also diagnostic (C-7: 150e152 ppm, C-5:
130e134 ppm, C-3: 115e120 ppm and C-2: 139e144 ppm). This
strongly supports that the NMR shift of H-5 can be used to provide
an initial indication of which regioisomer is produced, with further
supporting evidence being derived from more detailed NMR anal-
ysis, such as HSQC correlations. A ﬁnal conﬁrmation with NOESY or
HMBC would be required for unambiguous characterisation, but at
least in this manner one would have a quick indication of which
isomer to expect.
Although others have performed kinetic and computational
analyses to yield insights into the rearrangement mechanism, to
our knowledge, no isotopic labelling studies of imidazo[1,2-a]py-
rimidines have been performed to support the proposed mecha-
nism of the rearrangement. In order to establish whether the
transformation observed was a result of the Dimroth rearrange-
ment, we investigated the reaction of 15N-labelled amino-
pyrimidines 8c under basic conditions.
The ester 8c was ﬁrst subjected to the previously reported
Fig. 2. 2D NOESY spectra showing nOe correlations in compounds 8b and 11a.
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Scheme 3). Interestingly, we observed only limited conversion to
the other isomer, some hydrolysis in the case of the ester, but
mainly decomposition. The use of THF as a co-solvent has been
described as facilitating the rearrangement and minimizing
decomposition in other substrates [28]. Treatment of esters 8a and
8c under these conditions gave the corresponding carboxylic acids
11a and 11b in good yields (Scheme 3, [b]). The rearrangement was
also observed upon treatment of 8a with EtONa in EtOH allowing
access to the respective 3-substituted esters (12a-b). We further
wanted to investigate if a rearrangement takes place in this ring
system in the presence of acid or by photoactivation. No conversion
was observed in the presence of formic acid after 24 h or after
irradiation at 365 nm (100W) for 30min for either 2- and 3-
regioisomeric esters 8a or 11a.
Extensive NMR characterization veriﬁed the regiochemistry of
all the 15N-labelled compounds and showed that indeed the 15N
atom initially occupying position 1 in analogue 8cwas in position 4
in analogues 11b and 12b after the rearrangement had taken place.
A decrease in chemical shift was observed for 15N from 239.9 and
241.1 ppm for 8c and 8d respectively, to 188.5 and 187.7 ppm for
11b and 12b respectively, when the 15N was positioned at the ring
junctionwithin the bicyclic system in the two latter analogues, and
consistent with the change from sp2 to sp3 environments. Further
conﬁrmation came from the 1H-15N HMBC correlations for 8c and
12b (Fig. 3). For 8c all nJNH coupling constants of the labelled ni-
trogenwere very small (<1Hz), being unresolved in the 1H and the
1H-coupled 15N spectra. As such, the 15N HMBC correlation in-
tensities for 8c were very sensitive to the JNH value chosen for the
HMBC acquisition (5 or 2 Hz). This also meant correlations to
unlabelled nitrogen centres were of comparable intensity to those
of the labelled nitrogen in the 5 Hz optimised HMBC in particular
(NMR Supplementary Material). For 12b, the JNH couplings of H2
and H5 were clearly resolved in the 1H spectrum (3.0 and 1.3 Hz
respectively) and gave rise to the dominant correlations in the 5 Hz-optimised HMBC. Finally, the multiplicities of protons and carbons
neighboring 15N also changed accordingly (NMR Supplementary
Material).
Having investigated the spectroscopic properties of these
compounds, we next used this information to assess whether there
were any other apparent misassignments of such compound
structures in the literature. We conducted a literature search in
Reaxys (December 2017, Fig. 4): 9302 substances were found con-
taining the imidazo[1,2-a]pyrimidine core in 1426 research papers
and 936 patents. It was thus conﬁrmed that this is indeed a ubiq-
uitous scaffold. The quantity and quality of the data used to assign
structure for these examples was analysed in detail, as it was this
that was of particular interest. We then narrowed our search down
to 2,6- and 3,6-disubstituted analogues, because these were the
scaffolds of direct relevance to the studies we had conducted. 1354
2,6-Disubstituted imidazo[1,2-a]pyrimidines derivatives were re-
ported in 138 research papers and 116 patents. Out of the 1354
compounds only 284 were reported with 1H NMR data (in 44 out of
138 research papers and 29 out of 116 patents). Similar observa-
tions were noted for 3,6-disubstituted imidazo[1,2-a]pyrimidines
(355 reported compounds in 55 research papers and 47 patents),
where again only 73 out of 355 compounds had 1H NMR data re-
ported (25 research papers and 19 patents). Of particular note was
that the vast majority of these documents did not unambiguously
verify the structure using further crystallographic or 2D-NMR data.
Most tellingly, we were able to ﬁnd a matched pair of 1H NMR and
X-ray data in only in one patent and a single research paper. Ras-
sapali et al. [29] conﬁrmed their structure with X-ray in the total
synthesis of oroidin and related alkaloids. However, in this case the
authors were interested only in one of the two regioisomers and
spectroscopic data for the regioisomer was not provided. Also, in
the patent application WO2006071752 [30] the authors conﬁrmed
the structure of their 2-substituted carboxylic acid / ester de-
rivatives using X-ray crystallography, but again 1H NMR data is
provided only for the 2-regioisomer.
Fig. 3. 1H-15 N HMBC correlations in compounds 8c and 12b (spectra optimised to JNH¼ 2Hz for 8c and 5 Hz for 12b).
Fig. 4. Schematic representation of the literature ﬁndings. A. Imidazo[1,2-a]pyrimidines and sub-classes occurrence in the literature and respective spectral data B. Pie chart
showing the regioisomeric subclasses of interest. C: Pie chart illustrating the availability of structural characterization data in 2,6- and 3,6-disubstituted imidazo[1,2-a]pyrimidines
D. Pie chart illustrating the availability of 1H NMR data in carboxylic acid derivatives of 2,6- and 3,6-imidazo[1,2-a]pyrimidines and incidences of correct or incorrect regiochemical
assignments.
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derivatives, and our synthetic efforts were targeting such scaffolds,
we focused our search on this type of compound. It was very
concerning that out of 106 reported compounds in Reaxys only 21
had associated NMR data. The 1H NMR data available is reported in
Supplementary Table 2 (Supplementary Information). There we
looked for the characteristic H-5 shifts to assess the regiochemistry
of the compounds. Even in this small sample, we observed that 12
(>50%) compounds have potentially misassigned structures across
7 documents. This ﬁnding conﬁrms that this is a very importantissue that needs to be brought to the attention of the scientiﬁc
community.3. Conclusion
In order to explore further an unexpected Dimroth rearrange-
ment observed whilst synthesizing some imidazo[1,2-a]pyrimidine
derivatives, we synthesized unlabelled and 15N-labelled analogues
in order to unambiguously assign the regiochemistry of the 2- and
3-substituted isomers and elucidate the reactionmechanism. These
M. Chatzopoulou et al. / Tetrahedron 74 (2018) 5280e5288 5285studies supported a rearrangement mechanism involving addition
of hydroxide ion followed by ring opening. Conﬁrmation of struc-
ture with X-ray is the usual way to determine regioisomerism for
most derivatives, but for mono-substituted imidazo[1,2-a]pyrimi-
dines on the imidazole ring, the structure can be determined with a
NOESY or an HMBC experiment. In fact, the chemical shifts of the
pyrimidine ring protons in conjunctionwith an HSQC can also serve
as a ﬁrst indication, since the H-5 proton appears to be signiﬁcantly
deshielded in 3-substituted derivatives, due to the presence of the
carbonyl substituent. However, ﬁnal conﬁrmation with either two
2D-NMR experiments or X-ray crystallography would allow more
conﬁdence in the regiochemical assignment. This has potentially
far reaching consequences both in terms of similar effects with
related ring systems, but also provides a cautionary tale against
relying directly on published data for structural assignments.4. Experimental
4.1. General
All reactions involving moisture-sensitive reagents were carried
out under a nitrogen or argon atmosphere using standard vacuum
line techniques and glassware that was ﬂame dried and cooled
under nitrogen before use. Water was puriﬁed by an Elix® UV-10
system. All other reagents were used as supplied (analytical or
HPLC grade) without prior puriﬁcation. Thin layer chromatography
was performed on aluminium plates coated with 60 F254 silica.
Flash column chromatography was performed either on Kieselgel
60 silica on a glass column, or on a Biotage SP4 automated ﬂash
column chromatography platform. Melting points were recorded
on a EZ-Melt AutomatedMelting Point Apparatus (EZ Melt) and are
uncorrected. IR spectra were recorded on a Bruker Tensor 27 FT-IR
spectrometer. Selected characteristic peaks are reported in cm1.
NMR spectra were recorded on Bruker Avance III spectrometers (at
400, 500 or 600MHz) using the deuterated solvent stated and at rt
unless otherwise stated. The ﬁeld was locked by external refer-
encing to the relevant deuteron resonance. The JNH value for the
1H-15N HMBC acquisition was 5 Hz unless otherwise stated. Accu-
rate mass measurements were run on either a Bruker MicroTOF
internally calibrated with polyalanine, or a Micromass GCT instru-
ment ﬁtted with a Scientiﬁc Glass Instruments BPX5 column
(15m 0.25mm) using amyl acetate as a lock mass. For the UV
irradiation experiments a UVP High-Intensity UV Inspection Lamp
Model B-100AP was used.4.2. Ethyl 6-iodoimidazo[1,2-a]pyrimidine-2-carboxylate (1)
Ethyl bromopyruvate (1.51mL, 10.86mmol) was added drop-
wise to a solution of 2-amino-4-iodopyrimidine (0.80 g, 3.62mmol)
in dry THF (40mL). The mixture was stirred at rt for 2 h after which
it was ﬁltered. This solid was then dissolved in ethanol (20mL) and
reﬂuxed for 1 h. The reaction mixture was cooled down, concen-
trated in vacuo and partitioned between CH2Cl2 (20mL) and satu-
rated aqueous NaHCO3 (20mL). The organic layer was dried
(MgSO4), ﬁltered and concentrated in vacuo. Puriﬁcation by ﬂash
column chromatography (eluent 3040 C petrol/EtOAc, 3:1 to 1:6)
afforded 1 as a white solid (0.59 g, 52%): mp 209e211 C; nmax
(cm1) 1721 (C]O); 1H NMR (400MHz, CDCl3) 8.77 (d, J¼ 2.0 Hz,
1H), 8.69 (d, J¼ 2.0 Hz, 1H), 8.10 (s,1H), 4.45 (q, J¼ 7.0 Hz, 2H), 1.42
(t, J¼ 7.0 Hz, 3H); 13C NMR (100MHz, CDCl3) 162.6, 157.0, 146.1,
138.3, 114.8, 75.6, 61.7, 14.5; HRMS (ESIþ) C9H9O2N3127Iþ [MþH]þ
requires 317.9734; found 317.9725.4.3. General Method A. Synthesis of ethyl 6-arylimidazo[1,2-a]
pyrimidine-2-carboxylate
Ethyl 6-iodoimidazo[1,2-a]pyrimidine-2-carboxylate 1 (1 eq),
caesium ﬂuoride (2.5 eq), arylphenylboronic acid (2 eq), tri(o-tolyl)
phosphine (0.1 eq) and palladium acetate (0.05 eq) were dissolved
in 1,2-dimethoxyethane (0.1M) and themixturewas evacuated and
degassed. The reaction mixture was stirred at 90 C for 20 h, after
which it was diluted with CH2Cl2 and washed with H2O. The
organic layer was dried (MgSO4), ﬁltered and concentrated in vacuo.
The residue was puriﬁed by ﬂash column chromatography (eluent
3040 C petrol/EtOAc, 10:1 to 1:5). Representative spectra for cpd
2a are given below.4.3.1. Ethyl 6-(3-methoxyphenyl)imidazo[1,2-a]pyrimidine-2-
carboxylate (2a)
Yield: 75%. mp 207e208 C; nmax (cm1) 1722 (C]O); 1H NMR
(400MHz, CDCl3) 8.90 (d, J¼ 2.5 Hz, 1H), 8.57 (d, J¼ 2.5 Hz, 1H),
8.18 (s, 1H), 7.44 (t, J¼ 8.0 Hz, 1H), 7.14 (d, J¼ 8.0 Hz, 1H), 7.08 (s,
1H), 7.01 (dd, J¼ 8.0, 1.8 Hz, 1H), 4.47 (q, J¼ 7.0 Hz, 2H), 3.88 (s, 3H),
1.45 (t, J¼ 7.0 Hz, 3H); 13C NMR (100MHz, CDCl3) 163.0, 160.6,
152.8,147.6,138.6,134.9,130.8,130.5,124.6,119.5,115.5,114.4,113.2,
61.6, 55.6, 14.5; HRMS (ESIþ) C16H16O3N3þ [MþH]þ requires
298.1186; found 298.1183.4.4. General Method B. Synthesis of amides via route A
To a suspension of 2a (1 eq) in anhydrousMeOH (0.1M), CaCl2 (1
eq) and the appropriate amine (1 eq) were added and reﬂuxed for
1 h. The solvent was then removed in vacuo and 3a-ewere isolated
after ﬂash column chromatography (eluent 3040 C petrol/EtOAc,
4:1 to 1:1).4.4.1. (6-(3-Methoxyphenyl)imidazo[1,2-a]pyrimidin-2-
yl)(morpholino)methanone (3a)
Yield: 33%. mp 273e275 C; 1H NMR (500MHz, CDCl3) d 8.86 (d,
J¼ 2.5 Hz, 1H, H-7), 8.58 (d, J¼ 2.5 Hz, 1H, H-5), 8.18 (s, 1H, H-3),
7.50e7.40 (m, 1H, H-50), 7.15 (ddd, J¼ 7.7, 1.8, 0.9 Hz, 1H, H-60), 7.09
(t, J¼ 2.1 Hz, 1H, H-20), 7.01 (ddd, J¼ 8.3, 2.6, 0.9 Hz, 1H, H-40), 4.52
(t, J¼ 4.8 Hz, 2H, H-200), 3.89 (s, 3H, OCH3), 3.86e3.77 (m, 6H, H-200
and H-300); 13C NMR (125.5MHz, CDCl3) d 162.3 (C]O), 160.6 (C-30),
152.0 (C-7), 146.4 (C-9), 142.6 (C-2), 134.9 (C-10), 130.8 (C-50), 130.4
(C-5), 124.4 (C-6), 119.5 (C-60), 115.8 (C-3), 114.3 (C-40), 113.2 (C-20),
67.6 (C-300), 67.1 (C-300), 55.6 (OCH3), 47.5 (C-200), 43.4 (C-200); HRMS
(ESIþ) C18H19N4O3þ ([MþH]þ) requires 339.14572; found 339.14506.4.4.2. N-Ethyl-6-(3-methoxyphenyl)-N-methylimidazo[1,2-a]
pyrimidine-2-carboxamide (3d)
Yield: 10%. mp 178e180 C; 1H NMR (500MHz, CDCl3) d 8.84 (t,
J¼ 2.9 Hz, 1H, H-7), 8.58 (d, J¼ 2.5 Hz, 1H, H-5), 8.13 (s, 1H, H-3),
7.44 (app t, J¼ 8.0 Hz, H-50), 7.15 (ddd, J¼ 7.6, 1.8, 0.9 Hz, 1H, H-60),
7.08 (t, J¼ 2.1 Hz, 1H, H-20), 7.00 (ddd, J¼ 8.3, 2.6, 0.9 Hz, 1H, H-40),
4.15 (q, J¼ 7.1 Hz, 1.1H, CH2CH3 rotamer 1), 3.88 (s, 3H, OCH3), 3.62
(q, J¼ 7.2 Hz, 0.9H, CH2CH3 rotamer 2), 3.59 (s, 1.3H, NCH3 rotamer
1), 3.13 (s, 1.7H, NCH3 rotamer 2), 1.31 (t, J¼ 7.1 Hz, 1.7H, CH2CH3,
rotamer 1), 1.26 (t, J¼ 7.2 Hz, 1.3H, CH2CH3, rotamer 2); 13C NMR
(125.5MHz, CDCl3) d 163.6e163.2 (C]O), 160.5 (C-30), 151.6e151.5
(C-7), 146.5e146.4 (C-9), 143.5e143.3 (C-2), 135.1 (C-10), 130.8 (C-
50), 130.4 (C-5), 124.2 (C-6), 119.5 (C-60), 115.1 (C-3), 114.2 (C-40),
113.1 (C-20), 55.6 (OCH3), 45.7e43.8 (CH2CH3), 36.5e34.1 (NCH3),
14.3e12.2 (CH2CH3); HRMS (ESIþ) C17H19N4O2þ ([MþH]þ) requires
311.15080; found 311.14994.
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A solution of 7a-c (1 eq), HBTU (2.0 eq) and triethylamine (1.5
eq) in acetonitrile (0.1M) was stirred at rt for 15min. Then the
amine (1.5 eq) was added and the resultingmixturewas stirred at rt
for further 2 h. The solvent was evaporated in vacuo, and the res-
idue was dissolved in EtOAc and extracted with water. The organic
layer was washed with brine, dried over Na2SO4 and concentrated
in vacuo. Puriﬁcation via ﬂash column chromatography (eluent
3040 C petrol/EtOAc, 3:1 to 1:3) gave 3a-e (Yields:17e64%)
4.5.1. (6-(3-Methoxyphenyl)imidazo[1,2-a]pyrimidin-2-
yl)(morpholino)methanone (3a)
Yield: 64%. Same as the product obtained from Route A.
4.5.2. N-Ethyl-6-(3,4-dichlorophenyl)-N-methylimidazo[1,2-a]
pyrimidine-2-carboxamide (3b)
Yield: 40%. mp 201e202 C; 1H NMR (500MHz, CDCl3) d 8.79 (t,
J¼ 2.9 Hz, 1H, H-7), 8.60 (d, J¼ 2.5 Hz, 1H, H-5), 8.16 (s, 1H, H-3),
7.69 (d, J¼ 2.1 Hz, 1H, H-20), 7.61 (d, J¼ 8.3 Hz, 1H, H-50), 7.43 (dd,
J¼ 8.3, 2.2 Hz, 1H, H-60), 4.14 (q, J¼ 7.0 Hz, 1.1H, CH2CH3), 3.63 (q,
J¼ 7.2 Hz, 0.9H, CH2CH3), 3.59 (s, 1.4H, NCH3), 3.14 (s, 1.6H, NCH3),
1.32 (t, J¼ 7.0 Hz, 1.6H, CH2CH3), 1.26 (t, J¼ 7.1 Hz, 1.4H, CH2CH3);
13C NMR (125.5MHz, CDCl3) d 163.3e163.0 (C]O), 150.6 (C-7),
146.3 (C-9),144.0e143.8 (C-2),134.1 (C-10), 133.8 (C-20), 131.7 (C-50),
130.6e130.5 (C-50), 129.0 (C-20), 126.4 (C-60), 122.2e122.1 (C-6),
115.3e115.2 (C-3), 45.7e43.8 (CH2CH3), 36.5e34.1 (NCH3),
14.3e12.2 (CH2CH3); HRMS (ESIþ) C16H15Cl2N4Oþ ([MþH]þ) re-
quires 349.06229; found 349.06152.
4.5.3. N-Ethyl-6-(3-triﬂuorophenyl)-N-methylimidazo[1,2-a]
pyrimidine-2-carboxamide (3c)
Yield: 17%. mp 200 C; 1H NMR (500MHz, CDCl3) d 8.85 (dd,
J¼ 3.7, 2.5 Hz,1H, H-7), 8.66 (d, J¼ 2.6 Hz,1H, H-5), 8.18 (s,1H, H-3),
7.83 (s, 1H, H-40), 7.78 (d, J¼ 7.7 Hz, 1H, H-60), 7.76e7.72 (m, 1H, H-
20), 7.68 (app t, J¼ 7.7 Hz, 1H, H-50), 4.14 (q, J¼ 7.1 Hz, 1.1H, CH2CH3
rotamer 1), 3.62 (q, J¼ 7.2 Hz, 0.9H, CH2CH3 rotamer 2), 3.59 (s,
1.3H, NCH3 rotamer 1), 3.14 (s, 1.7H, NCH3 rotamer 2), 1.32 (t,
J¼ 7.1 Hz, 1.7H, CH2CH3, rotamer 1), 1.26 (t, J¼ 7.1 Hz, 1.3H, CH2CH3,
rotamer 2); 13C NMR (125.5MHz, CDCl3) d 163.4e163.0 (C]O),
150.9e150.8 (C-7), 146.4e146.3 (C-9), 144.0e143.7 (C-2), 134.7 (C-
10), 132.2 (q, J¼ 32.6 Hz, C-30), 130.8 (s, C-5), 130.5 (C-60), 130.3 (C-
50), 125.8 (q, J¼ 4.0 Hz, C-20), 124.0 (q, J¼ 3.9 Hz, C-40), 123.9 (q,
J¼ 272.6 Hz, CF3), 123.0 (d, J¼ 3.1 Hz, C-6), 115.3e115.2 (C-3),
45.7e43.8 (CH2CH3), 36.5e34.1 (NCH3), 14.3e12.2 (CH2CH3); HRMS




Yield: 49%. Same as the product obtained from Route A.
4.5.5. (6-(3-Methoxyphenyl)imidazo[1,2-a]pyrimidin-2-
yl)(pyrrolidin-1-yl)methanone (3e)
Yield: 63%. mp 214e216 C; 1H NMR (500MHz, CDCl3) d 8.84 (d,
J¼ 2.5 Hz, 1H, H-7), 8.58 (d, J¼ 2.5 Hz, 1H, H-5), 8.20 (s, 1H, H-3),
7.43 (app t, J¼ 8.0 Hz, 1H, H-50), 7.15 (ddd, J¼ 7.6, 1.8, 0.9 Hz, 1H, H-
60), 7.08 (t, J¼ 2.1 Hz, 1H, H-20), 7.00 (ddd, J¼ 8.3, 2.5, 0.9 Hz, 1H, H-
40), 4.25 (t, J¼ 6.8 Hz, 2H, H-200), 3.88 (s, 3H, OCH3), 3.71 (t,
J¼ 6.9 Hz, 2H, H-200), 2.00 (pd, J¼ 6.6, 1.1 Hz, 2H H-300), 1.93 (pd,
J¼ 6.7, 1.2 Hz, 2H H-300); 13C NMR (125.5MHz, CDCl3) d 161.8 (C]O),
160.5 (C-30), 151.5 (C-7), 146.7 (C-9), 143.6 (C-2), 135.1 (C-10), 130.8
(C-50), 130.4 (C-5), 124.2 (C-6), 119.5 (C-60), 114.9 (C-3), 114.2 (C-40),
113.1 (C-20), 55.6 (OCH3), 49.2 (C-200), 47.3 (C-200), 26.8 (C-300), 23.9
(C-300); HRMS (ESIþ) C18H19N4O2þ ([MþH]þ) requires 323.15080;found 323.14988.
4.6. General Method D. Synthesis of amides via route B
To a reﬂuxing solution of 2a-c (1 eq) in THF/EtOH (1:1, 0.15M),
1M NaOH in H2O (3 eq, 1:1) was added and the reaction reﬂuxed
for 3 h. It was then cooled to rt, pH was adjusted to 8 (NaHCO3) and
extracted with EtOAc. Then, the aqueous phase was further acidi-
ﬁed to pH 3 (1 N HCl), and the white precipitate formed was
collected, washed with Et2O to obtain crude 4a-c. The latter were
converted to the respective amides following the procedure
described in General Method C.
4.6.1. (6-(3-Methoxyphenyl)imidazo[1,2-a]pyrimidin-3-
yl)(morpholino)methanone (5a)
Yield from 2a: 37%. mp 204e205 C; 1H NMR (500MHz, CDCl3)
d 9.51 (d, J¼ 2.6 Hz,1H, H-5), 8.93 (d, J¼ 2.5 Hz,1H, H-7), 8.05 (s,1H,
H-2), 7.46e7.39 (m,1H, H-50), 7.19 (ddd, J¼ 7.7, 1.8, 0.9 Hz, 1H, H-60),
7.13 (dd, J¼ 2.5, 1.8 Hz, 1H, H-20), 6.99 (ddd, J¼ 8.2, 2.5, 0.9 Hz, 1H,
H-40), 3.93e3.89 (m, 4H, H-200), 3.88 (s, 3H, OCH3), 3.80 (dd, J¼ 5.7,
4.0 Hz, 4H, H-300); 13C NMR (125.5MHz, CDCl3) d 160.5 (C-30), 160.3
(C]O), 152.3 (C-7), 149.8 (C-9), 139.0 (C-2), 135.2 (C-10), 133.1 (C-5),
130.7 (C-50), 124.5 (C-6), 119.7 (C-60), 116.0 (C-3), 114.2 (C-40), 113.2
(C-20), 67.0 (C-300), 55.6 (OCH3), 44.4 (C-200); HRMS (ESIþ)
C18H19N4O3þ ([MþH]þ) requires 339.14572; found 339.14502.
4.6.2. N-Ethyl-6-(3,4-dichlorophenyl)-N-methylimidazo[1,2-a]
pyrimidine-3-carboxamide (5b)
Yield from 2b: 39%. mp 105e106 C; 1H NMR (500MHz, CDCl3)
d 9.74 (s, 1H, H-5), 8.87 (d, J¼ 2.6 Hz, 1H, H-5), 8.16 (s, 1H, H-2), 7.72
(d, J¼ 2.2 Hz,1H, H-20), 7.59 (d, J¼ 8.3 Hz,1H, H-50), 7.47 (dd, J¼ 8.3,
2.2 Hz, 1H, H-60), 3.71 (q, J¼ 7.2 Hz, 2H, CH2CH3), 3.29 (s, 3H, NCH3),
1.34 (s, 3H, CH2CH3); 13C NMR (125.5MHz, CDCl3) d 160.9 (C]O),
151.2 (C-7), 149.5 (C-9), 139.4 (C-2), 134.0 (C-30), 133.9 (C-40), 133.7
(C-5), 133.4 (C-10), 131.5 (C-50), 129.1 (C-20), 126.5 (C-60), 122.1 (C-6),
117.0 (C-3), 44.3 (CH2CH3), 35.8 (NCH3), 13.1 (CH2CH3); HRMS (ESIþ)
C16H15Cl2N4Oþ ([MþH]þ) requires 349.06229; found 349.06178.
4.6.3. N-Ethyl-6-(3-triﬂuorophenyl)-N-methylimidazo[1,2-a]
pyrimidine-3-carboxamide (5c)
Yield from 2c: 39%. mp 132e133 C; 1H NMR (500MHz, CDCl3)
d 9.77 (s, 1H, H-5), 8.98 (d, J¼ 2.6 Hz, 1H, H-7), 8.17 (s, 1H, H-2), 7.86
(d, J¼ 1.8 Hz, 1H, H-40), 7.81 (dt, J¼ 7.8, 1.4 Hz, 1H, H-60), 7.72 (dd,
J¼ 7.5, 1.6 Hz, 1H, H-20), 7.65 (app t, J¼ 7.8 Hz, 1H, H-50), 3.71 (q,
J¼ 7.2 Hz, 2H, CH2CH3), 3.29 (s, 3H, NCH3), 1.35 (t, J¼ 7.4 Hz, 3H,
CH2CH3); 13C NMR (125.5MHz, CDCl3) d 161.0 (C]O), 151.5 (C-7),
149.5 (C-9), 139.3 (C-2), 135.0 (C-10), 133.9 (s, C-5), 132.1 (q,
J¼ 32.5 Hz, C-30), 130.8 (C-60), 130.1 (C-50), 125.6 (q, J¼ 3.8 Hz, C-20),
124.2 (q, J¼ 3.8 Hz, C-40), 124.1 (q, J¼ 272.6 Hz, CF3), 123.0 (C-6),
117.0 (C-3), 44.4 (CH2CH3), 35.5 (NCH3), 13.1 (CH2CH3); HRMS (ESIþ)
C17H16F3N4Oþ ([MþH]þ) requires 349.12762; found 349.12651.
4.6.4. N-Ethyl-6-(3-methoxyphenyl)-N-methylimidazo[1,2-a]
pyrimidine-3-carboxamide (5d)
Yield from 2a: 41%. mp 96e97 C; 1H NMR (500MHz, CDCl3)
d 9.68 (s, 1H, H-5), 8.90 (d, J¼ 2.6 Hz, 1H, H-7), 8.15 (s, 1H, H-2), 7.40
(app t, J¼ 8.0 Hz, H-50), 7.18 (ddd, J¼ 7.6, 1.9, 0.9 Hz, 1H, H-60), 7.12
(t, J¼ 2.1 Hz, 1H, H-20), 6.96 (ddd, J¼ 8.2, 2.6, 0.9 Hz, 1H, H-40), 3.86
(s, 3H, OCH3), 3.68 (p, J¼ 7.3, 6.5 Hz, 2H, CH2CH3), 3.26 (s, 3H, NCH3),
1.32 (t, J¼ 7.1 Hz, 3H, CH2CH3); 13C NMR (125.5MHz, CDCl3) d 161.0
(C]O), 160.4 (C-30), 152.0 (C-7), 149.6 (C-9), 139.0 (C-2), 135.3 (C-
10), 133.5 (C-5), 130.6 (C-50), 124.2 (C-6), 119.7 (C-60), 116.8 (C-3),
114.1 (C-40), 113.1 (C-20), 55.6 (OCH3), 44.1 (CH2CH3), 35.3 (NCH3),
13.1 (CH2CH3); HRMS (ESIþ) C17H19N4O2þ ([MþH]þ) requires
311.15080; found 311.15001.
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yl)(pyrrolidin-1-yl)methanone (5e)
Yield from 2a: 45%. mp 138e139 C; 1H NMR (500MHz, CDCl3)
d 10.06 (d, J¼ 2.6 Hz, 1H, H-5), 8.94 (d, J¼ 2.6 Hz, 1H, H-7), 8.24 (s,
1H, H-2), 7.41 (app t, J¼ 8.0 Hz, 1H, H-50), 7.21 (ddd, J¼ 7.6, 1.8,
0.9 Hz, 1H, H-60), 7.14 (t, J¼ 2.1 Hz, 1H, H-20), 6.98 (ddd, J¼ 8.3, 2.6,
0.9 Hz, 1H, H-40), 3.88 (s, 3H, OCH3), 3.87e3.83 (m, 2H, H-200),
3.78e3.70 (m, 2H, H-200), 2.16e1.96 (m, 4H, H-300); 13C NMR
(125.5MHz, CDCl3) d 160.5 (C-30), 159.8 (C]O), 152.2 (C-7), 149.5
(C-9), 139.6 (C-2), 135.4 (C-10), 133.9 (C-5), 130.6 (C-50), 124.3 (C-6),
119.8 (C-60), 117.7 (C-3), 114.2 (C-40), 113.1 (C-20), 55.6 (OCH3), 48.7
(C-200), 47.1 (C-200), 26.8 (C-300), 24.1 (C-300); HRMS (ESIþ)
C18H19N4O2þ ([MþH]þ) requires 323.15080; found 323.15025.
4.7. 2-Amino-5-phenylpyrimidine (6)
4.7.1. Method 1
Based on a literature method [34] 2-amino-5-iodopyrimidine
(2.00 g, 9.05mmol), phenylboronic acid (1.66mg, 13.57mmol),
Pd(OAc)2 (20mg, 0.09mmol) and K3PO4$7H2O (3.84mg,
18.1mmol) in ethylene glycol (36mL) were heated at 80 C for
120min. The reaction was then allowed to cool to rt, and it was
added to brine, extracted with Et2O (3 50mL), dried over Na2SO4
and concentrated in vacuo. Then NaOH (3.6 g) was added and stir-
red for 2 h. Themixturewas added to brine and extractedwith Et2O
(3 100mL) to give 6 as a light yellow solid (1.40 g, 90%). mp
161e163 C (lit. 158e159 C [35]), 1H NMR (400MHz, MeOH-d4)
d 8.53 (s, 2H), 7.56e7.49 (m, 2H), 7.47e7.39 (m, 2H), 7.37e7.30 (m,
1H).
4.7.2. Method 2
A solution of 1M aq NaOH (5.0mL), 2-chloro-5-
phenylpyrimidine 6 (100mg, 0.53mmol) and NH4Cl (253mg,
4.72mmol) were added to a 10e20mL vial, sealed with a crimp cap
and placed in a CEM Discover Lab Mate reactor microwave cavity.
After irradiation at 150 C for 30min, the reaction mixture was
cooled to rt and the precipitate was ﬁltered, andwashedwithwater
to provide a white crystalline solid (55mg, 61%). mp 162e163 C
(lit. 158e159 C [35]), 1H NMR (400MHz, MeOH-d4) d 8.53 (s, 2H),
7.56e7.28 (m, 5H).
4.8. 2-Chloro-5-phenylpyrimidine (9)
Based on a literature method [31] 5-bromo-2-chloropyrimidine
(1.00mg, 5.17mmol), phenylboronic acid (1.26 g, 10.34mmol),
Pd(OAc)2 (58mg, 0.26mmol) and Na2CO3 (1.10 g, 10.34mmol) in
H2O/EtOH (4:1, 50mL) were heated at 45 C for 30min. The reac-
tion was then allowed to cool at rt, and it was added to brine,
extracted with CH2Cl2 (3 50mL), dried over Na2SO4 and
concentrated in vacuo. Puriﬁcation via ﬂash column chromatog-
raphy (eluent CH2Cl2) gave 8 as a white solid (1.57 g, 80%). mp
132 C (lit. 132 C [32]; 131e133 C [33]), 1H NMR (400MHz, CDCl3)
d 8.82 (s, 2H), 7.62e7.44 (m, 5H).
4.9. General Method E. Synthesis of 2-substituted 6-arylimidazo
[1,2-a]pyrimidines
To a solution of 6, 6a-c or 10 (1 eq) in DMF (0.1M) the appro-
priate bromo pyruvate reagent (2 eq) was added and the reaction
mixture was stirred under Ar at r.t. for 4 days. For the ethyl ester
derivatives, the reaction mixture was then poured into saturated
NaHCO3, extracted with CH2Cl2, washed with water, and brine,
dried over anhydrous MgSO4 and concentrated in vacuo. The esters
were puriﬁed with ﬂash column chromatography (eluent 3040 C
petrol/EtOAc, 3:1 to 1:1), followed by recrystallization from EtOH.For the acid derivatives, the reaction mixture was poured into
saturated NaHCO3, adjusted to pH 8 and extracted with CH2Cl2.
Then, the aqueous phase was adjusted to pH 3 with conc. HCl and
extracted with iPrOH/CHCl3 (1:3 v/v), dried over Na2SO4 and
concentrated in vacuo. The ﬁnal products were obtained after
recrystallization with EtOH. Representative spectra for cpds 8a-
d follow.4.9.1. Ethyl 6-phenylimidazo[1,2-a]pyrimidine-2-carboxylate (8a)
Yield: 47%. mp 234e235 C, vmax 1724 (CO) cm1, 1H NMR
(500MHz, DMSO‑d6) d 9.30 (d, J¼ 2.7 Hz, 1H), 9.06 (d, J¼ 2.6 Hz,
1H), 8.46 (s, 1H), 7.81e7.77 (m, 2H), 7.60e7.54 (m, 2H), 7.51e7.46
(m, 1H), 4.35 (q, J¼ 7.1 Hz, 2H), 1.34 (t, J¼ 7.1 Hz, 3H), 13C NMR
(125.5MHz, DMSO‑d6) d 162.4, 152.7, 146.9, 136.4, 133.4, 132.6,
129.4, 128.6, 126.8, 122.6, 116.8, 60.5, 14.2. HRMS (ESIþ) C15H14N3O2þ
([MþH]þ) requires 268.10805; found 268.10777.4.9.2. 6-Phenylimidazo[1,2-a]pyrimidine-2-carboxylic acid (8b)
Yield 20%. mp 232e233 C, vmax 3147 (OH), 1687 (CO) cm1, 1H
NMR (500MHz, DMSO‑d6) d 13.01 (bs, 1H), 9.31 (d, J¼ 2.6 Hz, 1H),
9.04 (d, J¼ 2.6 Hz,1H), 8.40 (s,1H), 7.82e7.77 (m, 2H), 7.60e7.54 (m,
2H), 7.51e7.46 (m, 1H), 13C NMR (125.5MHz, DMSO‑d6) d 163.8,
152.4, 146.8, 137.4, 133.5, 132.6, 129.3, 128.6, 126.8, 122.5, 116.5.
HRMS (ESIþ) C13H10N3O2þ ([MþH]þ) requires 240.07675; found
240.07682.4.9.3. 15N-Ethyl 6-phenylimidazo[1,2-a]pyrimidine-2-carboxylate
(8c)
Yield: 41%. mp 234e235 C, vmax 1712 (CO) cm1, 1H NMR
(500MHz, DMSO‑d6) d 9.30 (d, J¼ 2.7 Hz, 1H), 9.06 (d, J¼ 2.6 Hz,
1H), 8.46 (s, 1H), 7.81e7.76 (m, 2H), 7.59e7.53 (m, 2H), 7.50e7.46
(m, 1H), 4.35 (q, J¼ 7.1 Hz, 2H), 1.35 (t, J¼ 7.1 Hz, 3H), 13C NMR
(125.5MHz, DMSO‑d6) d 162.9 (d, J¼ 7.7 Hz), 153.2 (d, J¼ 3.8 Hz),
147.3 (d, J¼ 6.6 Hz), 136.9, 133.9, 133.1, 129.8, 129.1, 127.3, 123.1,
117.2, 61.0, 14.7, 15N NMR (60MHz, DMSO‑d6) d 239.9. HRMS (ESIþ)
C15H14N215NO2þ ([MþH]þ) requires 269.10509; found 269.10504.4.9.4. 15N-6-Phenylimidazo[1,2-a]pyrimidine-2-carboxylic acid
(8d)
Yield: 18%. mp 229e231 C, vmax (ﬁlm) 3147 (OH), 1687 (CO)
cm1, 1H NMR (500MHz, DMSO‑d6) d 13.02 (bs, 1H), 9.31 (d,
J¼ 2.7 Hz, 1H), 9.04 (d, J¼ 2.6 Hz, 1H), 8.40 (s, 1H), 7.81e7.76 (m,
2H), 7.59e7.53 (m, 2H), 7.51e7.46 (m, 1H), 13C NMR (125.5MHz,
DMSO‑d6) d 163.8 (d, J¼ 7.7 Hz), 152.4 (d, J¼ 4.3 Hz), 146.8 (d,
J¼ 6.1 Hz), 137.3, 133.5, 132.6, 129.3, 128.6, 126.8, 122.5, 116.5, 15N
NMR (60MHz, DMSO‑d6) d 241.1. HRMS (ESIþ) C13H10N215NO2þ
([MþH]þ) requires 241.07379; found 241.07370.4.10. 2-15N-Amino-5-phenylpyrimidine (10)
A solution of 1M aq NaOH (5.0mL), 2-chloro-5-
phenylpyrimidine 6 (100mg, 0.53mmol) and 15NH4Cl (257mg,
4.72mmol) were added to a 10e20mL vial, sealed with a crimp cap
and placed in a CEM Discover Lab Mate reactor microwave cavity.
After irradiation at 150 C for 30min, the reaction mixture was
cooled to rt and the precipitate was ﬁltered, andwashedwithwater
to provide a white crystalline solid (74mg, 81%). mp 161e163 C,
vmax 3146 (NH2) cm1, 1H NMR (400MHz, MeOH-d4, 9:1 mixture
d 8.43 (s, 2H), 7.50e7.45 (m, 2H), 7.42e7.37 (m, 2H), 7.30e7.23 (m,
1H); 8.53 (s, 2H), 7.57e7.52 (m, 2H), 7.45e7.42 (m, 2H), 7.37e7.32
(m, 1H). HRMS (ESIþ) C10H10N215Nþ ([MþH]þ) requires 173.08396;
found 173.08406.
M. Chatzopoulou et al. / Tetrahedron 74 (2018) 5280e528852884.11. 6-Phenylimidazo[1,2-a]pyrimidine-3-carboxylic acid (11a)
Following a similar procedure to the ﬁrst step of General
Method D, to a reﬂuxing solution of 8a (100mg) in THF/EtOH (1/
1mL), 1M NaOH in H2O (1.12mL in 1.5mL) was added and the
reaction reﬂuxed for 3 h. It was then cooled to rt, pH was adjusted
to 8 (NaHCO3) and extracted with EtOAc. Then, the aqueous phase
was further acidiﬁed to pH 3 (1 N HCl), and the white precipitate
formedwas collected, washedwith Et2O to obtain 11a (49mg, 55%).
mp 225e227 C, vmax (ﬁlm) 3286 (OH), 1692 (CO) cm1, 1H NMR
(500MHz, DMSO‑d6) d 13.56 (bs,1H), 9.68 (d, J¼ 2.5 Hz,1H), 9.17 (d,
J¼ 2.6 Hz, 1H), 8.50 (s, 1H), 7.86e7.77 (m, 2H), 7.62e7.55 (m, 2H),
7.56e7.48 (m, 1H), 13C NMR (125.5MHz, DMSO‑d6) d 161.1, 152.6,
149.1, 141.1, 133.3, 132.4, 129.5, 128.8, 127.2, 123.9, 115.1. HRMS
(ESIþ) C13H10N3O2þ ([MþH]þ) requires 240.07675; found 240.07669.
4.12. 15N-6-Phenylimidazo[1,2-a]pyrimidine-3-carboxylic acid
(11b)
Following a similar procedure to that for the preparation of 11a,
from 8c. Yield: 51%. mp 230e232 C, vmax (ﬁlm) 3286 (OH), 1686
(CO) cm1, 1H NMR (500MHz, DMSO‑d6) d 13.44 (bs, 1H), 9.67 (m,
1H), 9.13 (d, J¼ 2.6 Hz, 1H), 8.43 (d, J¼ 2.9 Hz, 1H), 7.85e7.77 (m,
2H), 7.63e7.55 (m, 2H), 7.54e7.47 (m, 1H), 13C NMR (125.5MHz,
DMSO‑d6) d 161.2 (d, J¼ 3.2 Hz), 152.0 (d, J¼ 4.2 Hz), 149.7 (d,
J¼ 8.0 Hz), 142.2 (d, J¼ 5.1 Hz), 133.5, 132.2 (d, J¼ 12.6 Hz), 129.4,
128.7, 127.1, 123.5, 115.0 (d, J¼ 16.3 Hz), 15N NMR (60MHz,
DMSO‑d6) d 188.5. HRMS (ESIþ) C13H10N215NO2þ ([MþH]þ) requires
241.07379; found 241.07368.
4.13. Ethyl 6-phenylimidazo[1,2-a]pyrimidine-3-carboxylate (12a)
A degassed suspension of 8a (52mg, 0.195mmol) and EtONa
(132mg, 1.95mmol) in EtOH (2.0mL) was heated at reﬂux for 18 h.
It was then cooled to rt, added to NaHCO3 (10mL), extracted with
CH2Cl2 (10mL 4), washed with water (10mL), and brine (10mL),
dried over MgSO4, and concentrated in vacuo. Puriﬁcation via ﬂash
column chromatography (eluent 3040 C petrol/EtOAc,
2:1/1:1), gave 12a as a white crystalline solid (15mg, 29%). mp
127e129 C, vmax (ﬁlm) 1694 (CO) cm1, 1H NMR (500MHz,
DMSO‑d6) d 9.59 (d, J¼ 2.6 Hz, 1H), 9.14 (d, J¼ 2.6 Hz, 1H), 8.46 (s,
1H), 7.83e7.76 (m, 2H), 7.60e7.54 (m, 2H), 7.52e7.46 (m, 1H), 4.39
(q, J¼ 7.1 Hz, 2H), 1.36 (t, J¼ 7.1 Hz, 3H), 13C NMR (125.5MHz,
DMSO‑d6) d 159.6,152.3,149.8,142.3,133.3,132.2,129.4,128.7,127.1,




Following a similar procedure to that for the preparation of 12a,
a degassed suspension of 8c (62mg, 0.231mmol) and EtONa
(158mg, 2.31mmol) in EtOH (2.0mL) was heated at reﬂux for 18 h.
It was then cooled to rt, added to NaHCO3 (10mL), extracted with
CH2Cl2 (10mL 4), washed with water (10mL), and brine (10mL),
dried over MgSO4, and concentrated in vacuo. Puriﬁcation via ﬂash
column chromatography (eluent 3040 C petrol/EtOAc,
2:1/1:1), gave 12b as a white crystalline solid (16mg, 26%). mp
129e131 C, vmax (ﬁlm) 1693 (CO) cm1, 1H NMR (500MHz,
DMSO‑d6) d 9.61 (dd, J¼ 2.6, 1.4 Hz,1H), 9.15 (dd, J¼ 2.6, 0.9 Hz,1H),
8.47 (d, J¼ 2.8 Hz, 1H), 7.84e7.77 (m, 2H), 7.62e7.55 (m, 2H),
7.53e7.47 (m, 1H), 4.40 (q, J¼ 7.1 Hz, 2H), 1.37 (t, J¼ 7.1 Hz, 3H), 13CNMR (125.5MHz, DMSO‑d6) d 160.1 (d, J¼ 2.9 Hz), 152.8 (d,
J¼ 4.5 Hz), 150.3 (d, J¼ 8.5 Hz), 142.8 (d, J¼ 5.1 Hz), 133.8, 132.7 (d,
J¼ 12.7 Hz), 129.9, 129.2, 127.6, 124.2,114.7 (d, J¼ 17.3 Hz), 61.1, 14.7,
15N NMR (60MHz, DMSO‑d6) d 187.7. HRMS (ESIþ) C15H14N215NO2þ
([MþH]þ) requires 269.10509; found 269.10472.
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